Eli Lilly (LLY) Receivables - Other (2012 - 2026)

Eli Lilly has reported Receivables - Other for 15 years, with the latest figure at $2.7 billion in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Other rose 39.73% year-over-year to $2.7 billion; the trailing twelve-month figure through Mar 2026 stood at $2.7 billion (up 39.73% YoY), and the FY2025 full-year result was $2.4 billion, up 5.51% from the prior year.
• Receivables - Other for Q1 2026 stood at $2.7 billion, up from $2.4 billion in the prior quarter.
• The five-year high for Receivables - Other was $3.3 billion in Q3 2025, with the low at $1.3 billion in Q2 2022.
• Historically, Receivables - Other has averaged $2.1 billion across 5 years, with a median of $2.1 billion in 2024.
• Annual changes were most pronounced in 2024 — Receivables - Other slipped 20.02% — and 2025, when it jumped 90.67%.
• Eli Lilly's Receivables - Other stood at $1.7 billion in 2022, then soared by 35.05% to $2.2 billion in 2023, then climbed by 1.08% to $2.3 billion in 2024, then gained by 5.51% to $2.4 billion in 2025, then grew by 14.74% to $2.7 billion in 2026.
• The last three Receivables - Other figures came in at $2.7 billion (Q1 2026), $2.4 billion (Q4 2025), and $3.3 billion (Q3 2025), per Business Quant data.